FindTrial
Sign In

Compound Danshen Dripping Pills for Maintenance Hemodialysis Patients with Coronary Artery Disease: effectiveness and safety assessment

Compound Danshen Dripping Pills for Secondary Prevention of Coronary Artery Disease in Maintenance Hemodialysis Population

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004327
Enrollment
Unknown
Registered
2014-01-26
Start date
2014-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance Hemodialysis Patients with Coronary Artery Disease

Interventions

Control group:Aspirin
Experimental:Compound Danshen Dripping Pills (CDDP)

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-80 years; 2. maintenance hemodialysis for over 3 months, with stable condition and treatment protocol; 3. diagnosed with coronary artery disease; 4. providing informed consent.

Exclusion criteria

Exclusion criteria: 1. being pregnant or lactating; 2. Severe primary disease like malignant tumor at active stage;decompensated liver cirrhosis; diseases of hematopoietic system; 3. Severe heart failure (NYHA IV),refractory hypertension (SBP>180mmHg, DBP>100mmHg on non-dialysis day); 4. Strengthened anticoagulant required due to PCI or CABG; 5. Awareness of allergy or intolerence to certain agents involved; 6. history of digestive tract hemarrage in the past 3months; 7. accompanied psychotic diseases; 8. Admitted to other clinical trials at the time.

Design outcomes

Primary

MeasureTime frame
endpoint event incidence;liver function test;Blood routine test;stool routine test and occult blood test;—

Secondary

MeasureTime frame
angina Scores;QoL Score;—

Countries

China

Contacts

Public ContactQizhan Lin

Guangdong Provincial Hospital of Chinese Medicine

linqizhan656635@163.com+86 13719366635

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026